You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD4 cell recovery

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Heart Failure, Mechanical Circulatory Support Trial in Ljubljana (CD34+ stem cell therapy)

Recruiting
  • Heart Failure
  • Mechanical Circulatory Support
  • CD34+ stem cell therapy
  • Ljubljana, Slovenia
    University Medical Center Ljubljana
Nov 22, 2023

T-cell Lymphoma, T-cell Leukemia Trial in Indianapolis (CD4CAR)

Recruiting
  • T-cell Lymphoma
  • T-cell Leukemia
  • CD4CAR
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
Dec 16, 2022

Chronic Myelomonocytic Leukemia Trial in Indianapolis (CD4CAR)

Not yet recruiting
  • Chronic Myelomonocytic Leukemia
  • CD4CAR
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
Oct 2, 2023

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

HIV Trial (Tetanus Toxoid Vaccine, Hydroxyurea, Didanosine)

Withdrawn
  • HIV Infections
  • Tetanus Toxoid Vaccine
  • +2 more
  • (no location specified)
Oct 28, 2021

HIV-1 Infection Trial in Puerto Rico, United States (Isotretinoin)

Completed
Has Results
  • HIV-1 Infection
  • Birmingham, Alabama
  • +14 more
Jul 31, 2021

Idiopathic CD4-Positive, T-Lymphocytopenia Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting
  • Idiopathic CD4-Positive
  • T-Lymphocytopenia
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 21, 2023

Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies Trial in Duarte (Cyclophosphamide, Pentostatin, Rabbit

Recruiting
  • Sickle Cell Disease
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jul 6, 2022

HIV Trial in Los Angeles, San Diego, Torrance (Maraviroc)

Completed
Has Results
  • HIV Infections
  • Los Angeles, California
  • +2 more
Aug 6, 2020

Idiopathic CD4 T Cell Lymphocytopenia Trial run by the NIAID (Gardasil 9)

Recruiting
  • Idiopathic CD4 T Cell Lymphocytopenia
  • Gardasil 9
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 10, 2023

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in

Suspended
  • Juvenile Myelomonocytic Leukemia
  • +27 more
  • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

Multiple Sclerosis, Clinically Isolated Syndrome Trial in Bordeaux (blood sample, cerebro-spinal fluid)

Recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • blood sample
  • cerebro-spinal fluid
  • Bordeaux, France
    CHU de Bordeaux - service de neurologie
Feb 2, 2022

T-cell Lymphoma Trial (CHOP + CD4, CHOP)

Terminated
Has Results
  • T-cell Lymphoma
  • (no location specified)
May 2, 2022

Optimising Cohorts for HIV Cure Interventions

Recruiting
  • HIV-1-infection
  • no intervention
  • Prahran, Victoria, Australia
    Alfred Health
May 1, 2023

T Cell Lymphoma, T-cell Leukemia Trial in Beijing (Efficacy of LCAR-T2C CAR-T cells)

Terminated
  • T Cell Lymphoma
  • T-cell Leukemia
  • Efficacy of LCAR-T2C CAR-T cells
  • Beijing, Beijing, China
  • +1 more
Aug 12, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory Trial in United States (LB1901)

Active, not recruiting
  • T-Cell Lymphoma
  • +4 more
  • LB1901
  • Rochester, Minnesota
  • +3 more
Feb 15, 2022

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 12, 2023

Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia Trial in Duarte (biological, procedure, drug, other)

Not yet recruiting
  • Recurrent Severe Aplastic Anemia
  • Refractory Severe Aplastic Anemia
  • Anti-Thymocyte Globulin
  • +7 more
  • Duarte, California
    City of Hope Medical Center
Feb 23, 2023

B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

Recruiting
  • B Cell Malignancies
  • Universal CD19-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

Interleukins in Periodontal Disease Progression

Recruiting
  • Periodontitis
  • Gingivitis
  • Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
  • Assiut, Asyut, Egypt
    Department of oral medicine, Periodontology, Oral diagnosis and
Nov 16, 2023

Sickle Cell Disease Trial in Saint Louis (Motixafortide, Natalizumab, Leukapheresis)

Not yet recruiting
  • Sickle Cell Disease
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 8, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/70 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022